Position of the Transparency Council – Amvuttra (vutrisiran)

At its meeting on 12 November 2024, the Transparency Council adopted position No. 118/2024 on the evaluation of the drug Amvuttra (vutrisyrate) under the drug program “Treatment of adult patients with stage I or II polyneuropathy in the course of hereditary transthyretin amyloidosis (ICD-10: E85.1)”

Publication of the position >>